Cyclo Therapeutics Inc. (CYTH): Price-to-Sales Ratio

Corporate company logo of CTD Holdings (CYTH)

Cyclo Therapeutics is pursuing the global expansion of Trappsol Cyclo to combat rare pathologies. The emerging ecosystem for treating genetic malfunctions slows the progression of Niemann-Pick disease. This chart on the GURU.Markets platform illustrates the price/sales multiple level, where 23.60 shows the current value of the metric. Planned laboratory workloads and the pristine condition of cleanroom equipment confirm stability.

CYTH: Cyclo Therapeutics P/S Multiple 07/04/2022 - 04/05/2025

Metric breakdowns and analytics for CTD Holdings (CYTH)

- share price and consensus valuation forecast:
Price Performance Chart cyclotherapeutics.com|CYTH - Price Target Chart
- stock exchange capitalization data:
Market Valuation CTD Holdings|CYTH - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share Cyclo Therapeutics|CYTH - Book Capitalization|Market Capitalization to Book Value Ratio cyclotherapeutics.com|CYTH - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Cyclo Therapeutics|CYTH - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Cyclo Therapeutics, Inc|CYTH - Company Aggregate Debts|Debts to Book Capitalization CTD Holdings|CYTH - Company Long-Term Debts|Company Current Liabilities Cyclo Therapeutics|Immediate Liquidity cyclotherapeutics.com
- earnings and valuation multiples information:
CYTH - Net Profit|Future Profit Cyclo Therapeutics|CYTH - Price to Earnings Ratio|Future Price to Earnings Cyclo Therapeutics Inc.|CYTH - Price/Earnings to Growth Ratio|Company Value to EBITDA CTD Holdings|CYTH - Operating profit before deduction of amortization|Earnings per share for the trailing year Cyclo Therapeutics|CYTH - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months cyclotherapeutics.com|CYTH - Earnings growth in current year|Expected earnings per share trend next year Cyclo Therapeutics
- issuer revenue and sales details:
CYTH - Revenue and Sales Volume|Company Expected Sales Volume cyclotherapeutics.com|CYTH - Price-to-Revenue Ratio|Forward Price to Sales CTD Holdings
General company analysis:CYTH cyclotherapeutics.com
Finished products of Cyclo Therapeutics

The P/S multiple compares current market capitalization to annual sales volume, allowing for an assessment of the premium paid for a business relative to its operating revenue. For Cyclo Therapeutics (CYTH), whose potential depends on attracting scientists and the success of clinical trials, the P/S history reflects market confidence in the future monetization of rare developments, signaling whether the asset is overvalued or undervalued.

Competing companies

VRTX (vrtx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alnylam ALNY|INSM (Insmed Inc.) - Price-to-Sales Ratio|United Therapeutics Corp. - P/S Multiple|Market Capitalization-to-Revenue Ratio BMRN (BioMarin Corp)|BBIO: P/S Multiple|BGM Group (BGM) - P/S Multiple|Price-to-Revenue Ratio Cogent Biosciences, Inc.|XERS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Keros Pharma (KROS)|Market Cap to Revenue Arcturus Corp ARCT|P/S Multiple ETON (Eton Pharmaceuticals)|P/S Multiple kamada.com KMDA|Fulcrum Therapeutics, Inc. - P/S Multiple|Abeona Therapeutics (ABEO) - Market Cap to Revenue|MREO (mereobiopharma.com) - Market Cap to Revenue|Price to Sales Protalix BioTherapeutics, Inc (PLX)|PLRX (Pliant Therapeutics Inc) - P/S Multiple|Market Cap to Revenue appliedtherapeutics.com (APLT)|Price-to-Revenue Ratio Rein Therapeutics (RNTX)|Price-to-Revenue Ratio GELS (gelteq.com)|Price-to-Revenue Ratio Aytu BioPharma AYTU|Chemomab Therapeutics Ltd (CMMB) - Price to Sales|SRXH: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PLRZ (Polyrizon Ltd)|AEZS (zentaris.com) - Market Cap to Revenue|INZY: Market Cap to Sales Volume|RPHM (Reneo Pharma) - P/S Multiple|CSCI: Market Capitalization-to-Revenue Ratio